TIDMHCM
RNS Number : 5742J
Hutchmed (China) Limited
27 April 2022
Annual General Meeting held on April 27, 2022 - Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April
27, 2022: HUTCHMED (China) Limited (" HUTCHMED" or the "Company")
(Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary
resolutions and special resolution put to its Annual General
Meeting ("AGM") held on April 27, 2022 were duly passed. The poll
results of the resolutions were as follows:
Number of Votes (%)*
Passed by
Ordinary Resolutions For Against Withheld(#) Shareholders
------------ ----------- --------------
To consider and adopt the audited
financial statements, and the
reports of the directors and independent
auditors for the year ended December
1. 31, 2021. 686,224,906 2,960 7,697,445 Yes
(99.9996%) (0.0004%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Mr TO Chi Keung, Simon
2(A). as a director. 635,955,913 51,971,563 5,997,835 Yes
(92.4452%) (7.5548%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Dr Weiguo SU as a
2(B). director. 686,123,331 1,804,145 5,997,835 Yes
(99.7377%) (0.2623%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Mr CHENG Chig Fung,
2(C). Johnny as a director. 685,947,446 1,980,030 5,997,835 Yes
(99.7122%) (0.2878%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Dr Dan ELDAR as a
2(D). director. 684,647,400 3,280,076 5,997,835 Yes
(99.5232%) (0.4768%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Ms Edith SHIH as a
2(E). director. 681,250,085 6,677,146 5,998,080 Yes
(99.0294%) (0.9706%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Mr Paul Rutherford
2(F). CARTER as a director. 686,252,741 1,674,735 5,997,835 Yes
(99.7566%) (0.2434%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Dr Karen Jean FERRANTE
2(G). as a director. 687,778,031 149,445 5,997,835 Yes
(99.9783%) (0.0217%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Mr Graeme Allan JACK
2(H). as a director. 674,126,615 12,957,617 6,841,079 Yes
(98.1141%) (1.8859%)
------------------------------------------ ------------ ----------- -------------- --------------
To re-elect Professor MOK Shu
2(I). Kam, Tony as a director. 670,413,452 17,501,649 6,010,210 Yes
(97.4558%) (2.5442%)
------------------------------------------ ------------ ----------- -------------- --------------
To appoint PricewaterhouseCoopers
and PricewaterhouseCoopers Zhong
Tian LLP as the auditors of the
Company for Hong Kong financial
reporting and U.S. financial reporting
purposes, respectively, and to
authorize the Directors to fix
3. the auditors' remuneration. 685,514,922 8,392,264 18,125 Yes
(98.7906%) (1.2094%)
------------------------------------------ ------------ ----------- -------------- --------------
Special Resolution
To grant a general mandate to
the directors of the Company to
4. issue additional shares.^ 683,701,055 4,221,351 6,002,905 Yes
(99.3864%) (0.6136%)
------------------------------------------ ------------ ----------- -------------- --------------
Ordinary Resolutions
To grant a general mandate to
the directors of the Company to
5(1). repurchase shares of the Company.^ 687,914,356 7,770 6,003,185 Yes
(99.9989%) (0.0011%)
------------------------------------------ ------------ ----------- -------------- --------------
To refresh the scheme mandate
limit under the Long Term Incentive
5(2). Plan.^ 601,082,095 53,973,751 38,869,465 Yes
(91.7604%) (8.2396%)
------------------------------------------ ------------ ----------- -------------- --------------
* Percentages rounded to 4 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
^ The full text of Resolutions 4 and 5 are set out in the Notice
of AGM.
All directors of the Company, namely Mr TO Chi Keung, Simon, Dr
Weiguo SU, Mr CHENG Chig Fung, Johnny, Dr Dan ELDAR, Ms Edith SHIH,
Mr Paul Rutherford CARTER, Dr Karen Jean FERRANTE, Mr Graeme Allan
JACK and Professor MOK Shu Kam, Tony, attended the AGM, either in
person or by means of electronic facilities.
Notes:
(1) Number of shares entitling the holders to attend and vote on
all the resolutions at the AGM: 864,530,850 shares.
(2) Number of shares entitling the holders to attend and abstain
from voting in favour as set out in Rule 13.40 of the Rules
Governing the Listing of Securities on The Stock Exchange of Hong
Kong Limited (the "Listing Rules") at the AGM: Nil.
(3) Number of shares for holders required under the Listing
Rules to abstain from voting at the AGM: Nil.
(4) The scrutineer for the poll at the AGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar
of the Company.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has more than 4,600 personnel across all
its companies, at the center of which is a team of about 1,500 in
oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch--med.com or follow us on LinkedIn .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 97 83 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley ,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGFLFLVSDIDFIF
(END) Dow Jones Newswires
April 27, 2022 09:30 ET (13:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
